Goldenwell Biotech Q2 FY26 net loss widens to $38,876; revenue remains no revenue - GWLL News | RalliesGoldenwell Biotech Q2 FY26 net loss widens to $38,876; revenue remains no revenue
G
GWLL• Expenses and balance sheet
- General and administrative expense rose to USD 34,776 for the quarter from USD 28,200; six-month expense edged up to USD 66,111 from USD 64,636.
- Cash totaled USD 11,143 at June 30, 2026; working capital was USD (398,195) with total liabilities of USD 427,173.
Quarterly and six-month results
- Goldenwell Biotech posted a net loss of USD 54,482 for the six months ended June 30, 2026, narrowing from USD 68,836.
- Quarterly net loss widened to USD 38,876 for the three months ended June 30, 2026 from USD 30,300.
- Revenue was unchanged at no revenue for the six months ended June 30, 2026.
